Checkpoint Therapeutics I... (CKPT)
| Bid | 4.04 |
| Market Cap | 355.64M |
| Revenue (ttm) | 41K |
| Net Income (ttm) | -56.24M |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -2.9 |
| Forward PE | 4.46 |
| Analyst | Hold |
| Ask | 4.15 |
| Volume | 675,201 |
| Avg. Volume (20D) | 2,717,883 |
| Open | 4.11 |
| Previous Close | 4.11 |
| Day's Range | 4.11 - 4.13 |
| 52-Week Range | 1.39 - 4.50 |
| Beta | 1.22 |
About CKPT
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-...
Analyst Forecast
According to 3 analyst ratings, the average rating for CKPT stock is "Hold." The 12-month stock price forecast is $4.1, which is a decrease of -0.49% from the latest price.
Stock Forecasts
1 month ago · proactiveinvestors.com
Checkpoint Therapeutics shares pop on acquisition by Sun PharmaCheckpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement,...
